Halozyme Therapeutics, Inc. (HALO) Misses Q4 EPS by 3c; Roche (RHHBY) Triggers $4M Milestone
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $98.66 -2%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported Q4 EPS of ($0.18), $0.03 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $2.41 million versus the consensus estimate of $5.25 million.
Roche (OTCBB: RHHBY) submission trigger $4 million milestone payment.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Roche (OTCBB: RHHBY) submission trigger $4 million milestone payment.
For earnings history and earnings-related data on Halozyme Therapeutics, Inc. (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- Vivos Therapeutics posts 35% revenue gain but widens net loss
Create E-mail Alert Related Categories
Corporate News, Earnings, FDARelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
